MedTrace Logo

Pilot Study on Evaluating the Geroprotective Effect of Metformin

NCT06459310 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2025-03-21

No results posted yet for this study

Summary

The objective of this research is to assess the efficacy of oral metformin in mitigating the aging process in middle-aged and elderly males, to pinpoint sensitive indicators of human senescence, and to offer innovative frameworks and scientific insights for pharmaceutical interventions in aging.

Conditions

  • Metformin
  • Aging

Interventions

DRUG

Metformin Hydrochloride tablet

Extended release oral tablets, 1000 mg/day, single dose

DRUG

Placebo

Oral tablets, 1000 mg/day, single dose

Sponsors & Collaborators

  • Institute of Zoology, Chinese Academy of Sciences

    collaborator OTHER_GOV

  • Beijing Institute of Genomics, Chinese Academy of Sciences

    collaborator OTHER_GOV

  • Merck Serono Co., Ltd., China

    collaborator INDUSTRY

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Guoguang Zhao, professor · Xuanwu Hospital, Beijing

  • Guoguang Zhao, professor · Xuanwu Hospital, Beijing

  • Jing Li, professor · Xuanwu Hospital, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2026-09-30
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06459310 on ClinicalTrials.gov